Kalpesh Parmar, Anshu Jha, Angel John, Aditya Manjunath, Odunayo Kalejaiye, Ali Reza Vosough, Bhaskar Somani, Joe Philip
Objective
This study evaluates the clinical outcomes of patients with suspected penile fractures who were managed conservatively after MRI excluded tunica albuginea rupture or fracture.
Methods
A retrospective review was conducted over a seven-year period, identifying patients who presented with symptoms suggestive of penile fracture. All patients who underwent MRI imaging to confirm or exclude the presence of a tunica albuginea rupture. Based on MRI findings, patients without confirmed fractures were managed conservatively, including instructions to avoid sexual activity and strenuous physical exertion. Follow-up assessments were conducted to monitor long-term complications, with a specific focus on erectile function, assessed via the International Index of Erectile Function (IIEF) and penile curvature.
Results
Of the 30 patients with suspected penile fractures, MRI excluded fractures in 63%. Among these conservatively managed patients, approximately 60% developed erectile dysfunction (ED) and 27% developed penile curvature. Even in cases without confirmed fractures, patients with contusions demonstrated significant post-injury complications.
Conclusion
MRI is effective in ruling out penile fractures, supporting the use of conservative management when fractures are not confirmed. However, conservative treatment alone is associated with a notable rate of complications, suggesting the potential benefit of early penile rehabilitation to address functional outcomes in these patients.
{"title":"Penile trauma management in absence of fracture: Long-term outcomes","authors":"Kalpesh Parmar, Anshu Jha, Angel John, Aditya Manjunath, Odunayo Kalejaiye, Ali Reza Vosough, Bhaskar Somani, Joe Philip","doi":"10.1002/bco2.70092","DOIUrl":"10.1002/bco2.70092","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study evaluates the clinical outcomes of patients with suspected penile fractures who were managed conservatively after MRI excluded tunica albuginea rupture or fracture.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective review was conducted over a seven-year period, identifying patients who presented with symptoms suggestive of penile fracture. All patients who underwent MRI imaging to confirm or exclude the presence of a tunica albuginea rupture. Based on MRI findings, patients without confirmed fractures were managed conservatively, including instructions to avoid sexual activity and strenuous physical exertion. Follow-up assessments were conducted to monitor long-term complications, with a specific focus on erectile function, assessed via the International Index of Erectile Function (IIEF) and penile curvature.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 30 patients with suspected penile fractures, MRI excluded fractures in 63%. Among these conservatively managed patients, approximately 60% developed erectile dysfunction (ED) and 27% developed penile curvature. Even in cases without confirmed fractures, patients with contusions demonstrated significant post-injury complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>MRI is effective in ruling out penile fractures, supporting the use of conservative management when fractures are not confirmed. However, conservative treatment alone is associated with a notable rate of complications, suggesting the potential benefit of early penile rehabilitation to address functional outcomes in these patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sandra Schönburg, Christian Gratzke, Kurt Miller, Erik Krieger, Patrick Papp, Laura Wiemer
Objective
To investigate whether storage or voiding symptoms respond more favourably to the use of Kranus Lutera, the first app-based digital therapeutic for male lower urinary tract symptoms (LUTS), using detailed item-level analysis of the IPSS questionnaire.
Materials and Methods
The present data represent a post-hoc analysis of the results of the BEST trial, a randomized controlled study evaluating the efficiency of the digital therapy Kranus Lutera. The study period lasted 12 weeks, conducted between 04/2023 and 11/2023. We assessed the mean change from baseline to 12 weeks for each of the seven IPSS items. Voiding symptoms (items 1, 3, 5 and 6) and storage symptoms (items 2, 4 and 7) were analysed separately.
Results
Participants using the digital therapeutic demonstrated statistically significant improvements across all IPSS items. Compared to the control group, the intervention group showed a significant and clinically relevant improvement in the primary endpoint (IPSS), with an overall reduction of −7.0 points (95% CI: −8.1 to −5.9, p < 0.0001). Notably, improvements in storage symptoms were consistently larger than those in voiding symptoms. The analysis of individual IPSS questions showed the greatest changes in the overall cohort for questions 1, 2 and 7 (each p < 0.0001). Patients with the single diagnosis BPH (N40) showed the greatest score reduction in questions 2 and 5 (each p < 0.0001), patients with OAB (N32.8) in questions 2, 4 and 7 (each p < 0.0001) and patients with BPH and OAB (N40 + N32.8) in questions 2, 3 and 7 (question 2 and 3 p < 0.0001, question 7 p = 0.0015). According to the analysis of individual IPSS questions, the greatest improvements were observed in frequency, nocturia and the feeling of incomplete bladder emptying.
Conclusion
These findings suggest that a structured app-based therapeutic may exert a stronger effect on storage symptoms than voiding symptoms in men with LUTS. This study confirms the value of the digital therapy as an integral part of the standard care for patients with male LUTS.
{"title":"Differential impact of digital therapy on storage and voiding LUTS: A post-hoc IPSS analysis from the BEST randomized controlled trial","authors":"Sandra Schönburg, Christian Gratzke, Kurt Miller, Erik Krieger, Patrick Papp, Laura Wiemer","doi":"10.1002/bco2.70069","DOIUrl":"https://doi.org/10.1002/bco2.70069","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To investigate whether storage or voiding symptoms respond more favourably to the use of Kranus Lutera, the first app-based digital therapeutic for male lower urinary tract symptoms (LUTS), using detailed item-level analysis of the IPSS questionnaire.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>The present data represent a post-hoc analysis of the results of the BEST trial, a randomized controlled study evaluating the efficiency of the digital therapy Kranus Lutera. The study period lasted 12 weeks, conducted between 04/2023 and 11/2023. We assessed the mean change from baseline to 12 weeks for each of the seven IPSS items. Voiding symptoms (items 1, 3, 5 and 6) and storage symptoms (items 2, 4 and 7) were analysed separately.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Participants using the digital therapeutic demonstrated statistically significant improvements across all IPSS items. Compared to the control group, the intervention group showed a significant and clinically relevant improvement in the primary endpoint (IPSS), with an overall reduction of −7.0 points (95% CI: −8.1 to −5.9, p < 0.0001). Notably, improvements in storage symptoms were consistently larger than those in voiding symptoms. The analysis of individual IPSS questions showed the greatest changes in the overall cohort for questions 1, 2 and 7 (each p < 0.0001). Patients with the single diagnosis BPH (N40) showed the greatest score reduction in questions 2 and 5 (each p < 0.0001), patients with OAB (N32.8) in questions 2, 4 and 7 (each p < 0.0001) and patients with BPH and OAB (N40 + N32.8) in questions 2, 3 and 7 (question 2 and 3 p < 0.0001, question 7 p = 0.0015). According to the analysis of individual IPSS questions, the greatest improvements were observed in frequency, nocturia and the feeling of incomplete bladder emptying.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings suggest that a structured app-based therapeutic may exert a stronger effect on storage symptoms than voiding symptoms in men with LUTS. This study confirms the value of the digital therapy as an integral part of the standard care for patients with male LUTS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70069","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145135643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Julia Mühlbauer, Luise Gottstein, Luisa Egen, Caelan Haney, Alexander Studier-Fischer, Evangelia Christodoulou, Giovanni E. Cacciamani, Keno März, Lena Maier-Hein, Stephan Maurice Michel, Allison Quan, Karl-Friedrich Kowalewski
Background and Objective
Preoperative risk stratification in renal tumour surgery is essential to enable risk-adjusted postoperative patient monitoring. Machine learning (ML) models predicting major complications (MCs) and acute kidney injuries (AKIs) following partial (PN) or radical nephrectomy (RN) have not been made, nor have they been compared with traditional logistic regression models.
Design, setting and participants
A total of 963 patients who underwent PN and RN between January 2017 and March 2023 at the University Medical Center Mannheim were included. The dataset consisted of 30 variables of interest– 18 descriptive and 12 predictor variables, which allowed for 7 predictor variables per event. The dataset was pre-processed, and ML models were created for MC and AKI. The selected models included Random Forest (RF), Support Vector Machines (SVMs), Stochastic Gradient Boosting, Neural Networks (NNs) and Elastic Net Logistic Regression models (ENETs).
Results and limitations
For major complications, the NN model had the best model fitting, with an AUROC of 0.762 [95%CI 0.611–0.912], a sensitivity of 0.86 [95%CI 0.80–0.92] and a Brier score of 0.17 [95%CI 0.11–0.23]. For AKI, the best fit model was created using a NN with an AUROC of 0.717 [95%CI 0.611–0.823], a sensitivity of 0.82 [95%CI 0.74–0.90] and a Brier score of 0.24 [95%CI 0.17–0.31]. The best performing models for both outcomes outperformed the ENETs.
Conclusions
The ML models provide valuable information for preoperative risk stratification of patients undergoing renal tumour surgery. This study suggests that NNs are the most appropriate models to stratify patients regarding the occurrence of MCs and AKIs, respectively. The models are made publicly available for reproducibility.
{"title":"AI-driven preoperative risk assessment in kidney cancer surgery: A comparative feasibility study of machine learning models","authors":"Julia Mühlbauer, Luise Gottstein, Luisa Egen, Caelan Haney, Alexander Studier-Fischer, Evangelia Christodoulou, Giovanni E. Cacciamani, Keno März, Lena Maier-Hein, Stephan Maurice Michel, Allison Quan, Karl-Friedrich Kowalewski","doi":"10.1002/bco2.70080","DOIUrl":"https://doi.org/10.1002/bco2.70080","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objective</h3>\u0000 \u0000 <p>Preoperative risk stratification in renal tumour surgery is essential to enable risk-adjusted postoperative patient monitoring. Machine learning (ML) models predicting major complications (MCs) and acute kidney injuries (AKIs) following partial (PN) or radical nephrectomy (RN) have not been made, nor have they been compared with traditional logistic regression models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design, setting and participants</h3>\u0000 \u0000 <p>A total of 963 patients who underwent PN and RN between January 2017 and March 2023 at the University Medical Center Mannheim were included. The dataset consisted of 30 variables of interest– 18 descriptive and 12 predictor variables, which allowed for 7 predictor variables per event. The dataset was pre-processed, and ML models were created for MC and AKI. The selected models included Random Forest (RF), Support Vector Machines (SVMs), Stochastic Gradient Boosting, Neural Networks (NNs) and Elastic Net Logistic Regression models (ENETs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results and limitations</h3>\u0000 \u0000 <p>For major complications, the NN model had the best model fitting, with an AUROC of 0.762 [95%CI 0.611–0.912], a sensitivity of 0.86 [95%CI 0.80–0.92] and a Brier score of 0.17 [95%CI 0.11–0.23]. For AKI, the best fit model was created using a NN with an AUROC of 0.717 [95%CI 0.611–0.823], a sensitivity of 0.82 [95%CI 0.74–0.90] and a Brier score of 0.24 [95%CI 0.17–0.31]. The best performing models for both outcomes outperformed the ENETs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The ML models provide valuable information for preoperative risk stratification of patients undergoing renal tumour surgery. This study suggests that NNs are the most appropriate models to stratify patients regarding the occurrence of MCs and AKIs, respectively. The models are made publicly available for reproducibility.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70080","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145135642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rodolfo Hurle, Anita Capalbo, Giovanni Lughezzani, Nicolò Maria Buffi, Francesco Sormani, Alessio Finocchiaro, Alberto Saita, Marco Paciotti, Vittorio Fasulo, Pietro Cavalli, Paolo Bianchi, Alessio Benetti, Pier Paolo Avolio, Rosanna Asselta, Giulia Soldà, Paolo Casale, Massimo Lazzeri
Objective
The contribution of germline DNA repair gene (gDRG) variants to bladder cancer (BC) susceptibility and progression is still poorly defined, particularly in European populations. This study aims to evaluate the prevalence and clinical implications of germline homologous recombination repair (HRR) gene variants in BC patients of European ancestry.
Methods
In this prospective case–control study, 75 BC patients attending follow-up at a single tertiary centre were screened for germline variants in 20 gDRGs. Patients were included regardless of disease stage and classified by pathogenicity (Class 3–5). Clinical characteristics and outcomes were compared between variant-positive and variant-negative patients.
Results
Among 75 eligible patients, 72 underwent successful germline sequencing. A total of 23 patients (30.6%) harboured at least one pathogenic, likely pathogenic, or VUS variant. The most frequently altered genes included ATM (n = 6), ATR (n = 4), BARD1 (n = 4), CHEK2 (n = 3) and PMS2 (n = 3). Eight patients (34.7%) had multiple variants, and one carried three variants. Notably, 25.8% of NMIBC and 50% of MIBC patients had gDRG variants. Moreover, 30% of patients with low-grade G1 disease harboured at least one variant. Patients with gDRG variants had a higher rate of histopathological variants (34.8% vs. 13.5%) and underwent radical cystectomy at a younger age (60 vs. 75 years, p < 0.05).
Conclusions
Germline HRR variants are prevalent in BC patients and may influence disease aggressiveness and treatment decisions. These findings support broader implementation of germline testing in BC and warrant further validation in larger cohorts.
{"title":"Germline homologous recombination repair (gHRR) variants in bladder cancer: Preliminary evidence and clinical implications","authors":"Rodolfo Hurle, Anita Capalbo, Giovanni Lughezzani, Nicolò Maria Buffi, Francesco Sormani, Alessio Finocchiaro, Alberto Saita, Marco Paciotti, Vittorio Fasulo, Pietro Cavalli, Paolo Bianchi, Alessio Benetti, Pier Paolo Avolio, Rosanna Asselta, Giulia Soldà, Paolo Casale, Massimo Lazzeri","doi":"10.1002/bco2.70077","DOIUrl":"https://doi.org/10.1002/bco2.70077","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The contribution of germline DNA repair gene (gDRG) variants to bladder cancer (BC) susceptibility and progression is still poorly defined, particularly in European populations. This study aims to evaluate the prevalence and clinical implications of germline homologous recombination repair (HRR) gene variants in BC patients of European ancestry.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this prospective case–control study, 75 BC patients attending follow-up at a single tertiary centre were screened for germline variants in 20 gDRGs. Patients were included regardless of disease stage and classified by pathogenicity (Class 3–5). Clinical characteristics and outcomes were compared between variant-positive and variant-negative patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 75 eligible patients, 72 underwent successful germline sequencing. A total of 23 patients (30.6%) harboured at least one pathogenic, likely pathogenic, or VUS variant. The most frequently altered genes included <i>ATM</i> (<i>n</i> = 6), <i>ATR</i> (<i>n</i> = 4), <i>BARD1</i> (<i>n</i> = 4), <i>CHEK2</i> (<i>n</i> = 3) and <i>PMS2</i> (<i>n</i> = 3). Eight patients (34.7%) had multiple variants, and one carried three variants. Notably, 25.8% of NMIBC and 50% of MIBC patients had gDRG variants. Moreover, 30% of patients with low-grade G1 disease harboured at least one variant. Patients with gDRG variants had a higher rate of histopathological variants (34.8% vs. 13.5%) and underwent radical cystectomy at a younger age (60 vs. 75 years, <i>p</i> < 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Germline HRR variants are prevalent in BC patients and may influence disease aggressiveness and treatment decisions. These findings support broader implementation of germline testing in BC and warrant further validation in larger cohorts.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70077","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145135644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Publio Cesar Cavalcante Viana, Marcelo Araújo Queiroz, Fabio Oliveira Ferreira, Adriano Basso Dias, Natally Horvat, Maurício Dener Cordeiro, Claudio Bovolenta Murta, Giuliano Betoni Guglielmetti, Rafael Ferreira Coelho, Leonardo Cardili, José Pontes Jr, William Carlos Nahas, Giovanni Guido Cerri
Objective
To evaluate the diagnostic performance of multiparametric MRI (mpMRI), mpMRI combined with PSA density (PSAd) and combined biopsy (CBx) in detecting clinically significant prostate cancer (csPCa) in men undergoing active surveillance, using radical prostatectomy (RP) specimens as the reference standard.
Patients and Methods
In this prospective single-centre study, 91 patients with low-risk prostate cancer under active surveillance underwent mpMRI, PSAd measurement, CBx and ultimately RP. mpMRI was reported using PI-RADS v2.0, and PSAd was dichotomised at 0.12 ng/ml/cm3. Diagnostic accuracy was compared using ISUP grade ≥2 and ≥3 thresholds. Radical prostatectomy pathology served as the reference standard.
Results
For detecting ISUP ≥3 cancer, mpMRI combined with PSAd achieved the highest sensitivity (93.3%) and negative predictive value (94.4%). CBx demonstrated the highest specificity (88.2%) and overall diagnostic balance (Youden index = 0.348). mpMRI alone showed intermediate performance. Differences in classification between strategies were statistically significant (McNemar p < 0.001).
Conclusions
mpMRI combined with PSAd provides high sensitivity and negative predictive value for ruling out aggressive prostate cancer, supporting its use as a non-invasive triage tool in active surveillance. CBx remains the most specific method for histological confirmation. These strategies should be used complementarily to optimise decision-making in active surveillance protocols.
目的评价多参数磁共振成像（mpMRI）、mpMRI联合PSA密度（PSAd）和联合活检（CBx）对主动监测男性临床显著性前列腺癌（csPCa）的诊断价值，并以根治性前列腺切除术（RP）标本为参考标准。在这项前瞻性单中心研究中，91名低风险前列腺癌患者在主动监测下接受了mpMRI、PSAd测量、CBx和最终RP。使用PI-RADS v2.0报告mpMRI， PSAd分为0.12 ng/ml/cm3。采用ISUP分级≥2和≥3阈值比较诊断准确性。以根治性前列腺切除术病理为参考标准。结果mpMRI联合PSAd对ISUP≥3级肿瘤的检测灵敏度最高（93.3%），阴性预测值最高（94.4%）。CBx表现出最高的特异性（88.2%）和总体诊断平衡（约登指数= 0.348）。mpMRI单独显示中等表现。不同策略的分类差异有统计学意义（McNemar p < 0.001）。结论mpMRI联合PSAd对排除侵袭性前列腺癌具有较高的敏感性和阴性预测值，支持其作为主动监测的无创分诊工具。CBx仍然是组织学证实的最具体方法。这些策略应相互补充，以优化主动监测协议中的决策。
{"title":"Multiparametric MRI combined with PSA density as a noninvasive rule-out strategy in active surveillance for prostate cancer","authors":"Publio Cesar Cavalcante Viana, Marcelo Araújo Queiroz, Fabio Oliveira Ferreira, Adriano Basso Dias, Natally Horvat, Maurício Dener Cordeiro, Claudio Bovolenta Murta, Giuliano Betoni Guglielmetti, Rafael Ferreira Coelho, Leonardo Cardili, José Pontes Jr, William Carlos Nahas, Giovanni Guido Cerri","doi":"10.1002/bco2.70079","DOIUrl":"10.1002/bco2.70079","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the diagnostic performance of multiparametric MRI (mpMRI), mpMRI combined with PSA density (PSAd) and combined biopsy (CBx) in detecting clinically significant prostate cancer (csPCa) in men undergoing active surveillance, using radical prostatectomy (RP) specimens as the reference standard.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>In this prospective single-centre study, 91 patients with low-risk prostate cancer under active surveillance underwent mpMRI, PSAd measurement, CBx and ultimately RP. mpMRI was reported using PI-RADS v2.0, and PSAd was dichotomised at 0.12 ng/ml/cm<sup>3</sup>. Diagnostic accuracy was compared using ISUP grade ≥2 and ≥3 thresholds. Radical prostatectomy pathology served as the reference standard.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>For detecting ISUP ≥3 cancer, mpMRI combined with PSAd achieved the highest sensitivity (93.3%) and negative predictive value (94.4%). CBx demonstrated the highest specificity (88.2%) and overall diagnostic balance (Youden index = 0.348). mpMRI alone showed intermediate performance. Differences in classification between strategies were statistically significant (McNemar p < 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>mpMRI combined with PSAd provides high sensitivity and negative predictive value for ruling out aggressive prostate cancer, supporting its use as a non-invasive triage tool in active surveillance. CBx remains the most specific method for histological confirmation. These strategies should be used complementarily to optimise decision-making in active surveillance protocols.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70079","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Baseline staging investigations for renal masses invariably include a CT of the chest. However, EAU guidelines have given a weak recommendation that CT chest can be omitted in incidental T1a tumours (≤4 cm) without systemic symptoms, due to the low incidence of pulmonary metastases. This study aimed to assess if a baseline staging CT chest has been clinically useful in a cohort with T1a renal tumours.
Methods
Consecutive patients with solid and cystic cT1a renal tumours were prospectively screened for eligibility to the NEST study (ISRCTN 18156881) at a single tertiary referral centre multidisciplinary team meeting (MDT). Four hundred consecutive eligible patients between 28/05/2019 and 13/01/2021 were included in this study. Electronic records were reviewed retrospectively for follow-up data. Seventeen patients with incomplete follow-up data were excluded.
Results
Of 383 included patients (63% male, median age 65 years, median tumour diameter 2.4 cm), 264 (69%) had a baseline CT chest as part of their clinical staging investigations. No thoracic renal metastases were diagnosed. Abnormalities were reported in 37/264 cases (14%), including indeterminate lung lesions in 32 patients that were deemed benign on further investigations, three synchronous primary lung tumours, one pre-existing mesothelioma and one pleural effusion related to known renal failure.
Conclusion
CT chest is of limited value in clinical staging investigations for cT1a renal tumours and has a negligible impact on subsequent renal tumour management. Rather, it triggered further investigations and follow-up for 14% of incidentalomas and ultimately detected concurrent incidental primary lung tumours in 1% of patients.
{"title":"Staging CT chest for cT1a renal masses: Does it change management?","authors":"Sanjana Ilangovan, Hannah Warren, Federica Sordelli, Thet Paing Oo, Pyae Phyo Tun, Prasad Patki, Faiz Mumtaz, Ravi Barod, Axel Bex, Maxine Tran","doi":"10.1002/bco2.70068","DOIUrl":"10.1002/bco2.70068","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Baseline staging investigations for renal masses invariably include a CT of the chest. However, EAU guidelines have given a weak recommendation that CT chest can be omitted in incidental T1a tumours (≤4 cm) without systemic symptoms, due to the low incidence of pulmonary metastases. This study aimed to assess if a baseline staging CT chest has been clinically useful in a cohort with T1a renal tumours.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Consecutive patients with solid and cystic cT1a renal tumours were prospectively screened for eligibility to the NEST study (ISRCTN 18156881) at a single tertiary referral centre multidisciplinary team meeting (MDT). Four hundred consecutive eligible patients between 28/05/2019 and 13/01/2021 were included in this study. Electronic records were reviewed retrospectively for follow-up data. Seventeen patients with incomplete follow-up data were excluded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 383 included patients (63% male, median age 65 years, median tumour diameter 2.4 cm), 264 (69%) had a baseline CT chest as part of their clinical staging investigations. No thoracic renal metastases were diagnosed. Abnormalities were reported in 37/264 cases (14%), including indeterminate lung lesions in 32 patients that were deemed benign on further investigations, three synchronous primary lung tumours, one pre-existing mesothelioma and one pleural effusion related to known renal failure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>CT chest is of limited value in clinical staging investigations for cT1a renal tumours and has a negligible impact on subsequent renal tumour management. Rather, it triggered further investigations and follow-up for 14% of incidentalomas and ultimately detected concurrent incidental primary lung tumours in 1% of patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70068","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Juanita Velasquez Ospina, Ansh Bhatia, Archan Khandekar, Aravindh Rathinam, Glenn Austin, Jonathan Katz, Robert Marcovich, Hemendra N. Shah
Objectives
To evaluate demographic characteristics and the prevalence of metabolic abnormalities in patients with pure struvite stones compared to those with mixed struvite and calcium oxalate stones.
Methods
We retrospectively reviewed 3001 stone analyses performed at our institution between August 2019 and April 2024. Patients who had a 24-hour urinary stone risk profile within six months of stone analysis were included. Exclusion criteria were a history of nephrolithiasis, bladder stones, neurogenic bladder or surgery for encrusted stent removal. Demographics, comorbidities and laboratory values were extracted using a HIPAA-compliant pipeline enhanced with a large language model (LLM). Patients with pure struvite stones were compared to those with mixed calcium oxalate–struvite stones. Statistical analysis was performed using RStudio v4.1.3.
Results
Forty-one patients met the inclusion criteria: 21 with pure struvite stones and 20 with mixed stones. While pure struvite stones were more common in females, the difference was not statistically significant. Demographics and comorbidities were similar between groups. Patients with pure struvite stones showed lower urinary levels of oxalate, potassium, citrate and uric acid, though not statistically significant. However, supersaturation of brushite, calcium oxalate and sodium urate was significantly lower in the pure struvite group (P < 0.05). At least one metabolic abnormality was present in 90.5% of the pure struvite group and in all patients with mixed stones.
Conclusions
Metabolic abnormalities are highly prevalent in both pure and mixed struvite stone formers. These findings support routine metabolic evaluation in patients with infection-related stones to guide long-term management.
{"title":"Metabolic abnormalities in pure vs. mixed struvite stone formers: A retrospective comparative analysis utilising large language models for data extraction","authors":"Juanita Velasquez Ospina, Ansh Bhatia, Archan Khandekar, Aravindh Rathinam, Glenn Austin, Jonathan Katz, Robert Marcovich, Hemendra N. Shah","doi":"10.1002/bco2.70072","DOIUrl":"10.1002/bco2.70072","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate demographic characteristics and the prevalence of metabolic abnormalities in patients with pure struvite stones compared to those with mixed struvite and calcium oxalate stones.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively reviewed 3001 stone analyses performed at our institution between August 2019 and April 2024. Patients who had a 24-hour urinary stone risk profile within six months of stone analysis were included. Exclusion criteria were a history of nephrolithiasis, bladder stones, neurogenic bladder or surgery for encrusted stent removal. Demographics, comorbidities and laboratory values were extracted using a HIPAA-compliant pipeline enhanced with a large language model (LLM). Patients with pure struvite stones were compared to those with mixed calcium oxalate–struvite stones. Statistical analysis was performed using RStudio v4.1.3.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Forty-one patients met the inclusion criteria: 21 with pure struvite stones and 20 with mixed stones. While pure struvite stones were more common in females, the difference was not statistically significant. Demographics and comorbidities were similar between groups. Patients with pure struvite stones showed lower urinary levels of oxalate, potassium, citrate and uric acid, though not statistically significant. However, supersaturation of brushite, calcium oxalate and sodium urate was significantly lower in the pure struvite group (P < 0.05). At least one metabolic abnormality was present in 90.5% of the pure struvite group and in all patients with mixed stones.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Metabolic abnormalities are highly prevalent in both pure and mixed struvite stone formers. These findings support routine metabolic evaluation in patients with infection-related stones to guide long-term management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70072","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fredrik Liedberg, Oskar Hagberg, Christel Häggström, Firas Aljabery, Truls Gårdmark, Staffan Jahnson, Tomas Jerlström, Viveka Ströck, Karin Söderkvist, Anders Ullén, Lars Holmberg, Johannes Bobjer
Objectives
To investigate the association between waiting time and outcomes in patients with upper tract urothelial carcinomas (UTUC).
Patients and methods
We studied a population-based cohort of 858 patients in BladderBaSe 2.0 subjected to extirpative surgery for UTUC 2015–2019 in Sweden. Diagnostic waiting time (from referral to diagnosis, reference <1 week), treatment waiting time (from diagnosis to surgery, reference <5 weeks) and total waiting time (reference <10 weeks) were investigated in relation to disease-specific (DSS) and overall survival (OS) by multivariable Cox regression models. To further explore these associations, stage progression from preoperatively recorded clinical tumour stage to pathological tumour stage in the extirpated specimen was assessed by logistic regression.
Results
Total waiting time was not associated with DSS, OS or stage progression. A diagnostic waiting time between 1 and 4 weeks was associated with better DSS (HR 0.57 [95% CI 0.35–0.94]) and OS (HR 0.60 [95% CI 0.41–0.87]). In the strata of patients with UTUC in the renal pelvis, a diagnostic waiting time > 4 weeks was associated with stage progression (OR 2.44 [95% CI 1.00–5.95]), and in patients with UTUC in the ureter, a treatment waiting time between 5 and 10 weeks was associated to worse DSS (HR 2.85 (95% CI 1.03–7.89).
Conclusions
In general, shorter care pathways were linked to beneficial survival estimates, yet some estimates may be influenced by selection bias due to prioritizing short waiting times for patients with advanced and/or overt symptomatic tumours. Stage progression with increased waiting time may indicate an underlying causal mechanism.
目的探讨上尿路上皮癌（UTUC）患者等待时间与预后的关系。患者和方法我们研究了一项基于人群的队列研究，在2015-2019年瑞典UTUC期间，在BladderBaSe 2.0中接受切除手术的858例患者。通过多变量Cox回归模型研究诊断等待时间（从转诊到诊断，参考文献1周）、治疗等待时间（从诊断到手术，参考文献5周）和总等待时间（参考文献10周）与疾病特异性（DSS）和总生存期（OS）的关系。为了进一步探讨这些关联，通过逻辑回归评估切除标本从术前记录的临床肿瘤分期到病理肿瘤分期的分期进展。结果总等待时间与DSS、OS或分期进展无关。诊断等待时间在1至4周之间与更好的DSS （HR 0.57 [95% CI 0.35-0.94]）和OS （HR 0.60 [95% CI 0.41-0.87]）相关。在肾盂UTUC患者中，诊断等待时间为4周与分期进展相关（OR 2.44 [95% CI 1.00-5.95]），而在输尿管UTUC患者中，等待治疗时间为5 - 10周与更差的DSS相关(HR 2.85 （95% CI 1.03-7.89）。总的来说，较短的治疗路径与有益的生存估计有关，但由于优先考虑晚期和/或明显症状肿瘤患者的较短等待时间，一些估计可能受到选择偏倚的影响。等待时间增加的阶段进展可能表明潜在的因果机制。
{"title":"Waiting time in diagnosis and extirpative surgery and association with survival and stage progression in upper tract urothelial carcinomas","authors":"Fredrik Liedberg, Oskar Hagberg, Christel Häggström, Firas Aljabery, Truls Gårdmark, Staffan Jahnson, Tomas Jerlström, Viveka Ströck, Karin Söderkvist, Anders Ullén, Lars Holmberg, Johannes Bobjer","doi":"10.1002/bco2.70093","DOIUrl":"10.1002/bco2.70093","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To investigate the association between waiting time and outcomes in patients with upper tract urothelial carcinomas (UTUC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and methods</h3>\u0000 \u0000 <p>We studied a population-based cohort of 858 patients in BladderBaSe 2.0 subjected to extirpative surgery for UTUC 2015–2019 in Sweden. Diagnostic waiting time (from referral to diagnosis, reference <1 week), treatment waiting time (from diagnosis to surgery, reference <5 weeks) and total waiting time (reference <10 weeks) were investigated in relation to disease-specific (DSS) and overall survival (OS) by multivariable Cox regression models. To further explore these associations, stage progression from preoperatively recorded clinical tumour stage to pathological tumour stage in the extirpated specimen was assessed by logistic regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Total waiting time was not associated with DSS, OS or stage progression. A diagnostic waiting time between 1 and 4 weeks was associated with better DSS (HR 0.57 [95% CI 0.35–0.94]) and OS (HR 0.60 [95% CI 0.41–0.87]). In the strata of patients with UTUC in the renal pelvis, a diagnostic waiting time > 4 weeks was associated with stage progression (OR 2.44 [95% CI 1.00–5.95]), and in patients with UTUC in the ureter, a treatment waiting time between 5 and 10 weeks was associated to worse DSS (HR 2.85 (95% CI 1.03–7.89).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In general, shorter care pathways were linked to beneficial survival estimates, yet some estimates may be influenced by selection bias due to prioritizing short waiting times for patients with advanced and/or overt symptomatic tumours. Stage progression with increased waiting time may indicate an underlying causal mechanism.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70093","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Muhammad Haider, Jeffrey J. Leow, Tobias Nordström, Ashkan Mortezavi, Peter Albers, Rakesh Heer, Prabhakar Rajan
Introduction
Prostate cancer (PCa) is the second most common cancer in men globally, with a rising incidence. Early detection through population-based screening by Prostate Specific Antigen (PSA) testing improves survival outcomes, at the expense of overdiagnosis and overtreatment of clinically insignificant disease. Here, we explore emerging tools for more effective PCa early detection and evaluate their potential roles for PCa screening.
Materials and Methods
Key articles on emerging adjuncts and alternatives to PSA for PCa early detection were identified.
Results
Multiparametric MRI (mpMRI) remains the gold standard modality for identifying clinically significant PCa and has been evaluated for screening. Newer imaging strategies incorporating biparametric MRI (bpMRI) or multiparametric ultrasound (mpUS) potentially offer similar accuracy to mpMRI. Saliva-derived polygenic risk scores (PRS) hold potential as a non-invasive screening tool to identify at-risk patient groups. Blood-based biomarker tests can improve risk stratification, reducing unnecessary biopsies while maintaining detection of clinically significant cancers compared to PSA alone. Urine-based biomarker tests have been examined for the early detection and risk stratification of clinically significant disease as adjuncts to PSA testing.
Conclusion
PSA is commonly used to detect early PCa, but its lack of specificity and associated overdiagnosis risk has led to controversy over its use for population-based screening. Imaging modalities such as mpMRI have reduced detection of clinically insignificant PCa, and emerging cost-effective alternatives, such as bpMRI and mpUS, show promise. Molecular biomarkers and PRS for risk stratification may help target imaging-based early detection more effectively to at-risk populations. Prospective randomised clinical trials are urgently needed to evaluate the performance of different modalities for population-wide screening. Future developments may involve technologies such as artificial intelligence and diagnostic tests that incorporate circulating tumour markers.
{"title":"Emerging tools for the early detection of prostate cancer","authors":"Muhammad Haider, Jeffrey J. Leow, Tobias Nordström, Ashkan Mortezavi, Peter Albers, Rakesh Heer, Prabhakar Rajan","doi":"10.1002/bco2.70081","DOIUrl":"10.1002/bco2.70081","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Prostate cancer (PCa) is the second most common cancer in men globally, with a rising incidence. Early detection through population-based screening by Prostate Specific Antigen (PSA) testing improves survival outcomes, at the expense of overdiagnosis and overtreatment of clinically insignificant disease. Here, we explore emerging tools for more effective PCa early detection and evaluate their potential roles for PCa screening.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Key articles on emerging adjuncts and alternatives to PSA for PCa early detection were identified.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Multiparametric MRI (mpMRI) remains the gold standard modality for identifying clinically significant PCa and has been evaluated for screening. Newer imaging strategies incorporating biparametric MRI (bpMRI) or multiparametric ultrasound (mpUS) potentially offer similar accuracy to mpMRI. Saliva-derived polygenic risk scores (PRS) hold potential as a non-invasive screening tool to identify at-risk patient groups. Blood-based biomarker tests can improve risk stratification, reducing unnecessary biopsies while maintaining detection of clinically significant cancers compared to PSA alone. Urine-based biomarker tests have been examined for the early detection and risk stratification of clinically significant disease as adjuncts to PSA testing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>PSA is commonly used to detect early PCa, but its lack of specificity and associated overdiagnosis risk has led to controversy over its use for population-based screening. Imaging modalities such as mpMRI have reduced detection of clinically insignificant PCa, and emerging cost-effective alternatives, such as bpMRI and mpUS, show promise. Molecular biomarkers and PRS for risk stratification may help target imaging-based early detection more effectively to at-risk populations. Prospective randomised clinical trials are urgently needed to evaluate the performance of different modalities for population-wide screening. Future developments may involve technologies such as artificial intelligence and diagnostic tests that incorporate circulating tumour markers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70081","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145101767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aidan Weitzner, Carlos Rivera Lopez, Joseph Cheaib, Michelle Higgins, Nirmish Singla
Objective
To characterize alcohol consumption and binge-drinking patterns among individuals with GU cancers (prostate, kidney, bladder and testicular) compared to a propensity-matched cohort without cancer in a large, nationally diverse population.
Materials and Methods
We conducted a retrospective, cross-sectional study utilizing data from the National Institutes of Health All of Us Research Program. Matching accounted for age, sex assigned at birth, smoking status, comorbidities and education/marital status. The primary outcome was self-reported drinking frequency. The secondary outcomes were self-reported binge-drinking frequency and Alcohol Use Disorders Identification Test (AUDIT-C) scores.
Results
Drinking and binge-drinking among individuals with GU malignancy (N = 11 522) closely resembled those of matched controls (N = 47 747), with the majority (53%) consuming at least 2–4 drinks per month. There was no significant association between GU cancer diagnosis and increased drinking frequency (OR: 0.99; p = 0.65), binge-drinking frequency (OR: 0.85; p: 0.055) or AUDIT-C (OR: 0.99; p =0.65). Individuals diagnosed with kidney cancer had reduced odds of higher alcohol use (OR: 0.76; p < 0.001) and AUDIT-C score (OR: 0.83; p < 0.001) compared to controls.
Conclusion
In this large cohort, including traditionally underrepresented minorities, alcohol use was highly prevalent among those with GU malignancies. Drinking behaviours were similar to individuals without cancer, underscoring the need for integration of lifestyle-focused interventions into survivorship care, as alcohol remains a common and modifiable behaviour with wide-ranging health implications.
目的：在全国范围内不同人群中，将GU癌（前列腺癌、肾癌、膀胱癌和睾丸癌）患者的饮酒和狂饮模式与倾向匹配的无癌人群进行比较。材料和方法我们进行了一项回顾性的横断面研究，利用了美国国立卫生研究院“我们所有人”研究项目的数据。匹配考虑了年龄、出生性别、吸烟状况、合并症和教育/婚姻状况。主要结果是自我报告的饮酒频率。次要结果是自我报告的酗酒频率和酒精使用障碍识别测试（AUDIT-C）得分。结果GU恶性肿瘤患者（N = 11 522）饮酒和酗酒与匹配对照组（N = 47 747）非常相似，其中大多数（53%）每月至少饮酒2-4次。GU癌诊断与饮酒频率增加（OR: 0.99; p =0.65）、酗酒频率增加（OR: 0.85; p: 0.055）或AUDIT-C （OR: 0.99; p =0.65）之间无显著相关性。与对照组相比，被诊断为肾癌的个体酒精使用较高的几率（OR: 0.76; p < 0.001）和AUDIT-C评分（OR: 0.83; p < 0.001）降低。结论：在这个庞大的队列中，包括传统上代表性不足的少数民族，酒精使用在GU恶性肿瘤患者中非常普遍。饮酒行为与未患癌症的个体相似，这强调了将以生活方式为重点的干预措施纳入幸存者护理的必要性，因为饮酒仍然是一种常见且可改变的行为，具有广泛的健康影响。
{"title":"Alcohol consumption among patients diagnosed with genitourinary cancers","authors":"Aidan Weitzner, Carlos Rivera Lopez, Joseph Cheaib, Michelle Higgins, Nirmish Singla","doi":"10.1002/bco2.70086","DOIUrl":"10.1002/bco2.70086","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To characterize alcohol consumption and binge-drinking patterns among individuals with GU cancers (prostate, kidney, bladder and testicular) compared to a propensity-matched cohort without cancer in a large, nationally diverse population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We conducted a retrospective, cross-sectional study utilizing data from the National Institutes of Health <i>All of Us</i> Research Program. Matching accounted for age, sex assigned at birth, smoking status, comorbidities and education/marital status. The primary outcome was self-reported drinking frequency. The secondary outcomes were self-reported binge-drinking frequency and Alcohol Use Disorders Identification Test (AUDIT-C) scores.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Drinking and binge-drinking among individuals with GU malignancy (N = 11 522) closely resembled those of matched controls (N = 47 747), with the majority (53%) consuming at least 2–4 drinks per month. There was no significant association between GU cancer diagnosis and increased drinking frequency (OR: 0.99; p = 0.65), binge-drinking frequency (OR: 0.85; p: 0.055) or AUDIT-C (OR: 0.99; p =0.65). Individuals diagnosed with kidney cancer had reduced odds of higher alcohol use (OR: 0.76; p < 0.001) and AUDIT-C score (OR: 0.83; p < 0.001) compared to controls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In this large cohort, including traditionally underrepresented minorities, alcohol use was highly prevalent among those with GU malignancies. Drinking behaviours were similar to individuals without cancer, underscoring the need for integration of lifestyle-focused interventions into survivorship care, as alcohol remains a common and modifiable behaviour with wide-ranging health implications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70086","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145101766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号